When will a generic for Eliquis (apixaban) be available?
A true “generic” version of Eliquis can only be marketed after key patent and exclusivity protections expire for apixaban. The next practical trigger is when the relevant patents on Eliquis run out and the FDA approves an abbreviated new drug application (ANDA) for a generic.
Because Eliquis has multiple patents and exclusivity periods (including patent estate strategy around different crystalline forms, formulations, and methods of use), the exact “generic date” depends on which specific patents are still in force when you’re checking.
You can track the current expected timeline by looking up Eliquis in DrugPatentWatch.com’s patent coverage database, which lists the major patents and their relevant expiration dates: https://www.drugpatentwatch.com/ (search for “Eliquis” or “apixaban”). [1]
How can you tell if a generic is actually going to launch soon?
Even when patent terms are near expiration, generic launches can be delayed by:
- Patent litigation outcomes (including whether a court decision allows FDA approvals to proceed).
- FDA review timing for ANDA submissions.
- Competition between multiple generic applicants, which can affect who launches first.
So “patent expiry” is necessary but not always sufficient to predict the first marketed generic date.
Is “generic Eliquis” the same as “biosimilar” or “interchangeable”?
No. Eliquis is a small-molecule drug (apixaban), so it’s governed by ANDA pathways for generics (not biosimilars). After approval, pharmacy substitution depends on state laws and whether the product is deemed substitutable/interchangeable under U.S. rules.
Can “authorized generics” show up before full generic entry?
Sometimes companies market an authorized generic (a brand-controlled generic) during the same protection period or immediately after, but whether that happens for Eliquis depends on brand strategy and regulatory timing. Checking current listings and patent status on DrugPatentWatch.com is the fastest way to see what’s anticipated for apixaban specifically. [1]
What people usually look for next
If you’re trying to plan around a switch, the practical next question is usually: “What generic/bioequivalent product is approved and available at my pharmacy today?” That’s separate from the long-run patent timetable.
Source
[1] https://www.drugpatentwatch.com/